CliffBio
biologic

Elelyso

taliglucerase alfa

Loss of exclusivityMay 2024projected — 12-year biologic exclusivity estimate
CompanyPfizer →See this company's full patent-cliff portfolio

Drug detail

Brand nameElelyso
Active ingredienttaliglucerase alfa
Strength200UNITS
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalMay 2012
Marketing statusRx

More from Pfizer

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Elelyso patent cliff — loss of exclusivity May 2024 | CliffBio